Trials Today

W8M-MC-LAA2 - Have a Body Mass Index (BMI) of ≥27 kilograms per square meter (kg/m²) - Have Type 2 Diabetes - Have a HbA1c ≥7.0 % (53 millimoles/mole (mmol/mol)) to ≤10.5% (91 mmol/mol) and treated with diet and exercise alone or with a stable dose of metformin (and not more than the locally approved dose) with or without a sodium-glucose cotransporter 2 (SGLT2) inhibitor for at least 3 months prior to screening W8M-MC-CWMM: - Have had a stable body weight for the 3 months prior to randomization (<5% body weight gain and/or loss)

W8M-MC-LAA2 - Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening - Have an on-going or history of bradyarrhythmia and/or sinus bradycardia - Have an elevated resting pulse rate (mean >100 beats per minute (bpm)) or reduced resting pulse rate (mean <60 bpm) at screening - Have any of the following cardiovascular conditions within 6 months prior to screening: - acute myocardial infarction - cerebrovascular accident (stroke) - unstable angina, or - hospitalization due to congestive heart failure - Have renal impairment measured as estimated glomerular filtration rate (eGFR) <45 milliliters per minute (mL/min)/1.73 m2 - Have a history of acute or chronic pancreatitis - Have fasting triglycerides >500 milligrams per deciliter (mg/dL) (5.7 mmol/L) at screening - All concomitant medications should be at a stable dose for at least 3 months prior to screening W8M-MC-CWMM - Have a prior or planned surgical treatment for obesity, except prior liposuction or abdominoplasty, if performed >1 year prior to screening. - Have type 1 diabetes mellitus, latent autoimmune diabetes in adults, or history of ketoacidosis or hyperosmolar coma. - Have poorly controlled hypertension. - Have a history of symptomatic gallbladder disease within the past 2 years - Have signs and symptoms of any liver disease other than nonalcoholic fatty liver disease. - Have a lifetime history of suicide attempts.